Canada: Recall: Teva-Levocarbidopa Tablet 250mg/25mg (English Only)
Health Canada announces that Teva Canada Limited is recalling two lots (Lot 35211134B and Lot 35211134C) of Teva-Levocarbidopa (levodopa/carbidopa) Tablet 250mg/25mg distributed to retail level across the Canadian provinces due to out-of-specification on dissolution during stability testing. 

Please refer to the following website in Health Canada for details: 

In Hong Kong, Carbidopa & Levodopa Tab 25/250mg (Teva) (HK-49645) is a pharmaceutical product registered by The International Medical Company Limited (International), and is a prescription-only medicine. As confirmed with International, the affected batches have not been imported into Hong Kong. 

Ends/Thursday, Feb 1, 2018 
Issued at HKT 16:00